Relevium Announces Agreement with Neptune Wellness for MaxSimil®
Summary
MONTREAL, April 30, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:RLV), (OTCQB:RLLVF) and (Frankfurt: 6BX ) (the“Company” or “Relevium”) , is pleased to announce the signing of a product development, supply and commercialization agreement with Neptune Wellness Solutions (TSX: NEPT ) (NASDAQ: NEPT ) for MaxSimil®, a patented fish oil monoglyceride omega 3 technology.Aurelio Useche, Relevium’s CEO “We are very pleased to partner with Neptune Wellness to develop new formulations combining MaxSimil® technology with plant derivatives and other nutraceutical ingredients, which will form part of current and future exclusive science-based brands” Mr. Useche continued: “The MaxSimil technology could prove to be a real differentiator for products marketed through our subsidiaries BGX Health and Biocannabix Health and their brands”Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products.Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering.The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.